Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...149150151152153154155156157158159...208209»
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Enrollment open:  Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis (clinicaltrials.gov) -  Jun 25, 2021   
    P2/3,  N=529, Recruiting, 
    Continuous administration of mecapegfilgrastim could keep the incidence of neutropenia to a relatively low level. Not yet recruiting --> Recruiting
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib. (Pubmed Central) -  Jun 24, 2021   
    The objective of present work is to evaluate possible interactions among four clinically-used vascular epidermal growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKIs), including apatinib, cabozantinib, sorafenib, and sunitinib, with epidermal growth factor receptor (EGFR)-TKI gefitinib...In addition, cabozantinib, sorafenib, and sunitinib expressed no interaction with gefitinib. The results of the present study may provide a basis and valuable information for the development of treatment strategies.
  • ||||||||||  Lamprene (clofazimine) / Novartis
    FDA event, Journal:  High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2. (Pubmed Central) -  Jun 24, 2021   
    Currently, there are no FDA-licensed drugs to treat arenavirus infection except for the off-labeled use of ribavirin...Five drug candidates were identified, including mycophenolic acid, benidipine hydrochloride, clofazimine, dabrafenib, and apatinib, for having strong anti-LCMV effects...We also found mycophenolic acid, clofazimine, dabrafenib, and apatinib can inhibit the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Owing to their FDA-approved status, these drug candidates can potentially be used rapidly in the clinical treatment of arenavirus and SARS-CoV-2 infection.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
    Biomarker, Clinical, P2 data, Journal, PD(L)-1 Biomarker, IO biomarker:  Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. (Pubmed Central) -  Jun 24, 2021   
    Owing to their FDA-approved status, these drug candidates can potentially be used rapidly in the clinical treatment of arenavirus and SARS-CoV-2 infection. Higher baseline TILs or a greater increase of tumor-infiltrating CD8 T cells during therapy, lower baseline plasma HGF/IL-8, a decrease of plasma IL-8, an increase of plasma TIM-3/CD152 during therapy, higher baseline CD4 T cells or B cells proportion in blood are potential biomarkers for combinational anti-angiogenesis and immunotherapy in advanced TNBC patients.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  PERMEATE: A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) -  Jun 24, 2021   
    P2,  N=78, Active, not recruiting, 
    However, adverse events were serious and should be carefully monitored from the beginning of apatinib treatment. Not yet recruiting --> Active, not recruiting | Trial completion date: Nov 2020 --> Dec 2022 | Trial primary completion date: Nov 2019 --> Apr 2021
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial initiation date, Trial primary completion date:  Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer (clinicaltrials.gov) -  Jun 24, 2021   
    P1/2,  N=30, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting | Trial completion date: Nov 2020 --> Dec 2022 | Trial primary completion date: Nov 2019 --> Apr 2021 Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Initiation date: Jan 2021 --> Nov 2019 | Trial primary completion date: Dec 2021 --> Sep 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open:  Glioblastoma Response Prediction to Apatinib (clinicaltrials.gov) -  Jun 24, 2021   
    P=N/A,  N=18, Recruiting, 
    Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Initiation date: Jan 2021 --> Nov 2019 | Trial primary completion date: Dec 2021 --> Sep 2020 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    PK/PD data, Preclinical, Journal:  The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. (Pubmed Central) -  Jun 23, 2021   
    Apatinib suppresses the CYP450 based metabolism of buspirone in a mixed mechanism and boosted the blood exposure of prototype drug and 6-OH buspirone dramatically. Therefore, extra caution should be taken when combining apatinib with buspirone in clinic.
  • ||||||||||  fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine, Lynparza (olaparib) / Merck (MSD), AstraZeneca, Zejula (niraparib) / GSK, J&J, Takeda
    Journal:  Analysis of PARP inhibitors induced anemia in advanced and relapsed epithelial ovarian cancer (Pubmed Central) -  Jun 23, 2021   
    One of the common adverse effects of PARP inhibitors is anemia, which mostly happened in the first 3 months of treatment. In the treatment of EOC, PARP inhibitor-related anemia mainly manifest as macrocytic orthochromatic anemia, and most patients with normal serum iron and transferrin.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial primary completion date:  Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC (clinicaltrials.gov) -  Jun 23, 2021   
    P2,  N=40, Recruiting, 
    In the treatment of EOC, PARP inhibitor-related anemia mainly manifest as macrocytic orthochromatic anemia, and most patients with normal serum iron and transferrin. Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2021 --> Jul 2022
  • ||||||||||  HR021618 / Jiangsu Hengrui Pharma
    Enrollment open:  HR021618 in Moderate to Severe Pain After Abdominal Surgery (clinicaltrials.gov) -  Jun 23, 2021   
    P2,  N=60, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2021 --> Jul 2022 Not yet recruiting --> Recruiting
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health
    Clinical, Journal:  Sight-threatening Complication of Cicatricial Ectropion in a Patient with Lamellar Ichthyosis - Case Report. (Pubmed Central) -  Jun 22, 2021   
    The patient was referred to a dermatologist and was started on systemic retinoid acitretin at a dose of 0.5 mg/kg per day...Infection in the cornea can rapidly progress to corneal melting in patients with severe cicatricial ectropion. A good patient outcome depends on the interdisciplinary approach to patient management by the ophthalmologist, dermatologist, and plastic surgeon.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharma
    Journal:  Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole. (Pubmed Central) -  Jun 22, 2021   
    Erythromycin, cyclosporine, and voriconazole can inhibit the metabolism of flumatinib in vitro. Accordingly, co-administration of erythromycin and cyclosporine with flumatinib increased the plasma concentration and the systemic exposure of flumatinib in rats, which indicated that lower doses should be considered in clinical practice.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
    Clinical, P2 data, Journal:  Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial. (Pubmed Central) -  Jun 22, 2021   
    Accordingly, co-administration of erythromycin and cyclosporine with flumatinib increased the plasma concentration and the systemic exposure of flumatinib in rats, which indicated that lower doses should be considered in clinical practice. This study showed that in HER2-positive operable or locally advanced breast cancer, the tpCR rate of P + EC-TH neoadjuvant therapy was about twice as high as that of EC-TH neoadjuvant therapy reported in other trials, with tolerable side effects.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Clinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib. (Pubmed Central) -  Jun 22, 2021   
    Herein, we reported two PPC patients with different targetable gene mutations who both responded dramatically to the PD-1 inhibitor camrelizumab combined with the oral anti-angiogenic drug anlotinib: one harbouring a BRAF V600E mutation with positive PD-L1 expression, few tumour-infiltrating lymphocytes (TILs) and abundant tumour blood vessels; and the other exhibiting a MET exon 14 skipping mutation with PD-L1 overexpression, scattered TILs and abundant tumour blood vessels. Our findings suggest that PD-1 inhibitor combined with anlotinib may be a potential treatment for PPC patients, and abundant tumour vessels should be investigated as a possible therapeutic biomarker.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS. (Pubmed Central) -  Jun 22, 2021   
    This method presented satisfactory results in terms of specificity, precision (coefficient of variation of intra-day and inter-day:1.4-6.6 %), accuracy (92.6-105.4 %), matrix effects (96.9-107.2 %), extraction recovery (90.5-99.4 %), as well as stability in human plasma and even whole blood under certain conditions. This sensitive, rapid and simple method was successfully applied to the analysis of sorafenib, lenvatinib and apatinib for therapeutic drug monitoring in hepatocellular carcinoma patients, and it was expected to be applied to further study about clarifying the concentration- efficacy and concentration-toxic relationship of sorafenib, lenvatinib, and apatinib in hepatocellular carcinoma patients.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Herceptin (trastuzumab) / Roche
    Clinical, Journal:  Effective treatment of apatinib for chemotherapy-refractory advanced gastric carcinoma with AFP-secretion and HER2-positivity: A case report. (Pubmed Central) -  Jun 22, 2021   
    The patient received first-line (i.e., S-1 plus oxaliplatin) and second-line (i.e., docetaxel) chemotherapy combined with trastuzumab for two cycles, respectively...It was speculated that AFP-secretion status could contribute to the chemoresistance of HER2-positive GC. Apatinib may be a promising anticancer agent in the case of advanced AFP-producing and HER2-positive GC.
  • ||||||||||  recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
    Enrollment open, Monotherapy:  Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia ? Stage (clinicaltrials.gov) -  Jun 21, 2021   
    P3,  N=405, Recruiting, 
    Molecular targeted drug therapy is effective and safe in patients with advanced gastric cancer, and the prognosis of patients is satisfactory, without the proliferation and metastasis of cancer cells. Not yet recruiting --> Recruiting